+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Amyotrophic Lateral Sclerosis Drug"

Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis (ALS) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 133 Pages
  • Global
From
From
Lou Gehrig's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Lou Gehrig's disease - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 240 Pages
  • Global
From
From
Amyotrophic Lateral Sclerosis - Pipeline Insight, 2024 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 240 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2024

  • Clinical Trials
  • June 2024
  • 447 Pages
  • Global
From
Central Nervous System Therapeutic Market - Product Thumbnail Image

Central Nervous System Therapeutic Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
From
From
EXSERVAN Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EXSERVAN Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
CNM-Au8 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CNM-Au8 Emerging Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
TIGLUTIK, Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

TIGLUTIK, Drug Insight and Market Forecast - 2032

  • Report
  • August 2022
  • 30 Pages
  • Global
From
From
Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Loading Indicator

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease. The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more